Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.
Department of Pediatrics, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, Philadelphia 19104, USA. Orange@mail.med.upenn.edu
Jordan S
JS
Orange
Elham M
EM
Hossny
Catherine R
CR
Weiler
Mark
M
Ballow
Melvin
M
Berger
Francisco A
FA
Bonilla
Rebecca
R
Buckley
Javier
J
Chinen
Yehia
Y
El-Gamal
Bruce D
BD
Mazer
Robert P
RP
Nelson
Dhavalkumar D
DD
Patel
Elizabeth
E
Secord
Ricardo U
RU
Sorensen
Richard L
RL
Wasserman
Charlotte
C
Cunningham-Rundles
D001249:Asthma / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000628:therapy; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000628:therapy; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects; D001523:Mental Disorders / Q000628:therapy; D009422:Nervous System Diseases / Q000628:therapy; D018357:Respiratory Syncytial Virus Infections / Q000209:etiology / Q000628:therapy; D012306:Risk; D012871:Skin Diseases / Q000628:therapy
D016756:Immunoglobulins, Intravenous